Urinary Formaldehyde Concentration After Methenamine Therapy in Patients on Intermittent Catheterization

Milap C. Nahata, PharmD, Britt A. Cummins, MS, Donald C. McLeod, MS, and David O. Weichers, MD Columbus, Ohio

Although ascorbic acid is routinely used as a urinary acidifier in conjunction with methenamine therapy, it produces an inconsistent pH-lowering effect.¹⁻⁴ Cranberry juice has also been used for urine acidification, but its effect on urine pH is reported to be transient.^{5,6} The effect of ascorbic acid and cranberry juice on urine pH and formaldehyde concentration in catheterized patients receiving methenamine mandelate was recently reported.⁷ Although the urinary formaldehyde concentrations were higher in patients receiving urinary acidifiers compared with those receiving methenamine mandelate alone, the urine cultures remained positive in most patients. Each of these patients had an indwelling Foley catheter and the inefficacy of methenamine treatments can perhaps be explained, in part, by the continuous drainage of urine. Based on in vitro studies, it has been suggested that even in an acidic urine (pH 5 to 6), methenamine requires 30 to 90 minutes to generate inhibitory concentration of formaldehyde.8,9 Two patients undergoing methenamine therapy and with intermittent urinary catheterization were studied, and markedly higher formaldehyde concentrations were found in these patients than in patients with indwelling Foley catheters.

Methods

Two patients (a 22-year-old man and 30-yearold woman) with cerebral vascular accident and a history of chronic bacteriuria were enrolled into the study. The patients were catheterized for a period of 5 to 10 minutes every 6 hours and were to receive chronic methenamine therapy for prophylaxis of urinary infection. The patients were afebrile, and the bacterial cultures were negative. The patients did not have any known abnormality of the urinary tract and the serum creatinines were less than 1.1 mg/100 mL. Informed consent was obtained prior to the study. The patients did not receive any medication except for those on the study protocol for at least one week before and during the study, and a regular hospital diet was followed throughout.

The patients received the three treatments as follows: methenamine mandelate granules, 1 g four times daily alone (X); with ascorbic acid, 1 g four times daily (Y); and with ascorbic acid and cranberry cocktail (33 percent juice), 250 mL four times daily (Z). The drugs were administered about two hours before catheterization.

Each treatment was continued for five days. Two days were allowed to achieve the maximal formaldehyde concentration from the assigned regimen, and urine samples were obtained four times daily approximately two hours after each treatment and at the end of catheterization period during the remaining three days of therapy. The weekend served as a "washout" period before institution of the next treatment.

© 1983 Appleton-Century-Crofts

From the Colleges of Pharmacy and Medicine, The Ohio State University, and the Department of Pharmacy, Mount Carmel Medical Center, Columbus, Ohio. Requests for reprints should be addressed to Dr. Milap C. Nahata, College of Pharmacy, Ohio State University, 500 West 12th Avenue, Columbus, OH 43210.

Continued on page 400

times daily

Treatment*	Patient 1		Intermittent Catheter Patient 2		Patients With Indwelling Foley Catheter ($n = 27$)	
	рН	Formaldehyde Concentration (µg/mL)	рН	Formaldehyde Concentration (µg/mL)	рН	Formaldehyde Concentration (µg/mL)
X	5 67 + 0.22	118.8 ± 25.0	5.75 ± 0.61	64.3 ± 45.0	6.19 ± 0.50	19.6 ± 10.2
Y	5.99 ± 0.37	112.3 ± 50.0	5.51 ± 0.28	143.0 ± 77.0	6.08 ± 0.60	30.0 ± 16.3
Z	5.89 ± 0.20	102.0 ± 60.0	6.21 ± 0.53	92.9 ± 61.0	5.60 ± 0.50	$39.4~\pm~23.1$

Ising pH and Formaldehyde Concentration

All urine specimens were immediately refrigerated, and were tested within an hour for pH and within four hours for formaldehvde concentration. The preliminary studies showed that the urine pH and the formaldehyde concentration did not change during the storage period. A digital pH meter was used for pH measurements. The method of Chen and Chafetz¹⁰ was used to determine formaldehyde as 3,5-diacetyl-1,4-dihydro-2,6-lutidine, formed by the Hantzsch reaction with acetylacetone and ammonia. The coefficient of variation for identical samples was less than 7 percent. Each subject's urine was analyzed 36 times for pH and formaldehyde concentration, 12 times on each of the three treatments. Urinary formaldehyde concentrations in the range of 10 to 28 μ g/mL have been reported to be bacteriostatic. greater than 28 μ g/mL bactericidal, and below 10 μ g/mL subtherapeutic.¹¹ In vitro studies,^{8,9} have suggested, however, that formaldehyde concentration above 25 µg/mL be considered bacteriostatic and above 50 µg/mL bactericidal, particularly with an exposure time of less than 2 hours.

Results

As shown in Table 1, the mean pH ranged from 5.67 to 5.99 in patient 1 and from 5.51 to 6.21 in patient 2. The lowest pH was seen with treatment X in one patient and with treatment Y in another. The mean urinary formaldehyde concentrations were substantially higher than the concentrations observed in the 27 patients studied previously.7 In

patient 1, the mean formaldehyde concentrations ranged from 102.0 to 118.8 μ g/mL, and in patient 2 these values ranged from 64.3 to 143.0 μ g/mL. The highest mean formaldehyde concentration of 118.8 μ g/mL was observed with treatment X in patient 1 and 143.0 µg/mL with treatment Y in patient 2. Urinary formaldehyde concentrations were lower in both patients after treatment Z compared with treatment Y. The urinary formaldehyde concentrations in both patients were always in the bactericidal range, and the weekly urine cultures remained negative throughout the study.

Comment

The results suggest that the urinary formaldehyde concentration following methenamine treatments in patients catheterized intermittently may be two- to fivefold higher than in patients with indwelling Foley catheters.7 It is important to consider the difference in the present and previous study conditions. First, the higher formaldehyde concentration in the present study may have been caused by the intermittent catheterization providing adequate time for the conversion of methenamine to formaldehyde. This is supported by in vitro observations^{8,9} that the continuous drainage of urine in patients with indwelling Foley catheter does not provide the minimum of 30 minutes for adequate formation of formaldehyde. Second, the presence of urea-splitting Proteus microorganisms

Continued on page 402

Continued from page 400

may alkalinize the urine and thus decrease the urinary formaldehyde concentration. This does not appear to account for the large observed difference because most patients with acidic urine pH in the previous study did not have Proteus species. The authors can find no published data to indicate that Escherichia coli and Klebsiella species substantially alkalinize the urine. Third, the two patients in the present study were young adults, while the patients in the previous study were elderly (aged 60 to 76 years). Although no data are available about the effect of age on the generation of formaldehyde from methenamine, it seems unlikely that age was related to the marked differences, as none of the patients in either study had renal dysfunction.

In this study, each of three methenamine regimens resulted in bactericidal formaldehyde concentration. Further long-term clinical studies are needed to demonstrate any therapeutic differences in regimens studied and in patients undergoing intermittent vs continuous urinary catheterization.

References

1. McDonald DF, Murphy GP: Bacteriostatic and acidifying effects of methionine, hydrolyzed casein, and acco-bic acid on the urine. N Engl J Med 261:803, 1959

2. Murphy FJ, Zelman S, Mau W: Ascorbic acid as a urinary acidifying agent: Part 2. Its adjunctive role in chronic urinary infections. J Urol 94:300, 1965 3. Travis LB, Dodge WF, Mintz AA, et al: Urinary acidification with ascorbic acid. J Pediatr 67:1176, 1965

4. Nahata MC, Shimp L, Lampman T, McLeod DC: Effect of ascorbic acid on urine pH in man. Am J Hosp Pharm 34:1234, 1977 5. Fellers CR, Redmon BC, Parrott EM: Effect of cran-

berries on urinary acidity and blood alkali reserves. J Nutr 6:455, 1933

6. Bodel PT, Cotran R, Kass EH: Cranberry juice and the antibacterial action of hippuric acid. J Lab Clin Med 54: 881, 1959 7. Nahata MC, Cummins BA, McLeod DC, et al: Effect

of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. Eur J Clin Pharmacol 22: 281, 1982

8. Musher DM, Griffith DP: Generation of formaldehyde from methenamine: Effect of pH and concentration, and antibacterial effect. Antimicrob Agents Chemother 6: 708, 1974

9. Musher DM, Griffith DP, Ritchie Y: Generation of formaldehyde from methenamine: Effect of urinary flow and residual volume. Invest Urol 13:380, 1976 10. Chen TM, Chafetz L: Selective determination of free

urinary formaldehyde after oral dosage with methenamine mandelate. Invest Urol 10:212, 1972

11. Pearman JW, Peterson GJ, Nash JB: The antimicrobial activity of urine of paraplegic patients receiving methenamine mandelate. Invest Urol 16:91, 1978

The Relationship of Continuity of Care to Age, Sex, and Race

Philip Sloane, MD, and Claudia Egelhoff, MSPH Chapel Hill, North Carolina

Continuity of care has been identified as one of the distinguishing characteristics of good primary care.1 Family medicine in particular regards continuity of care as a major ideal and seeks to teach

and promote continuity in its educational programs.² These attempts to foster continuity should be paralleled by efforts to evaluate it, since the determinates of continuity and its influence on health outcomes are largely unknown.3 A number of authors have sought to measure the overall continuity of care provided by a practice,4-6 but their results have been difficult to compare because the authors used differing measures of continuity.

Continued on page 404

© 1983 Appleton-Century-Crofts

THE JOURNAL OF FAMILY PRACTICE, VOL. 16, NO. 2: 402-405, 1983

From the Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Requests for reprints should be addressed to Dr. Philip Sloane, Department of Family Medicine, Trailer 15, 269H, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 27514